Cryo-Cell International, Inc

Cryo-Cell International is a U.S.-based cellular processing and cryogenic storage company focused on preserving umbilical cord blood and cord tissue stem cells for families, public transplant use, and related biostorage applications. Founded in 1989, it was the first private cord blood bank to separate and store stem cells in 1992 and has built a long operating history in newborn stem cell banking. The company also manufactures and sells its PrepaCyte® CB processing system, which is used in cord blood processing. In addition to its family banking business, Cryo-Cell is expanding into third-party cold storage through ExtraVault and is developing cellular therapy capabilities at its Durham, North Carolina facility.

4,6 %

76,6 %

−7,7 %

−1,3 %

0.59

0.57

— Cryo-Cell International, Inc
%
Family cord blood and cord tissue banking85% Collection, processing, and long-term cryogenic storage of newborn cord blood and cord tissue for private family use.
Public cord blood banking2% Processing and storage of cord blood stem cells for public transplant use through registry-linked programs.
Processing technology and product sales1% Sales of PrepaCyte® CB processing systems and related product revenue tied to cord blood processing technology.
Third-party biostorage and biorepository services12% ExtraVault cold storage services for biopharma companies, healthcare institutions, and other external customers.

Cryo-Cell's core customers are expectant parents who enroll newborns in private cord blood and cord tissue banking...

  • Private family banking customersprimary

    Expectant parents who purchase cord blood and cord tissue collection, processing, and multiyear storage for potential future family medical use.

  • Public transplant networksecondary

    Registry-linked transplant centers and public health users that rely on publicly banked cord blood units for stem cell transplantation.

  • Biopharma and healthcare storage clientsemerging

    Third-party pharmaceutical companies and medical institutions that buy ExtraVault cold storage and inventory management services.

  • Technology and processing customersemerging

    Customers and partners associated with PrepaCyte® CB processing technology and related product sales.

Cryo-Cell is headquartered in Oldsmar, Florida, and its U.S.-based business operations, including processing and...

  • •Headquartered in Oldsmar, Florida, where executive and operating functions are based
  • •Primary processing and cryogenic storage operations are in Durham, North Carolina
  • •U.S. market is the core source of private banking enrollments and storage revenue
  • •Central America is served through license agreements in six countries
  • •Public cord blood units are connected to the NMDP registry and international networks
  • •Geographic concentration in the U.S. makes operations sensitive to domestic regulation

Cryo-Cell's strategy is to defend its core private cord blood banking franchise while using its long operating history...

01
Expand ExtraVault biostorage servicesshort-term

This creates a new revenue stream from the Durham facility and reduces reliance on the family banking market.

02
Grow private cord blood and cord tissue enrollmentsshort-term

The core business depends on new family enrollments and recurring storage contracts.

03
Develop adjacent cellular therapy capabilitiesmedium-term

MSC manufacturing and related lab services could extend the company's stem cell platform into higher-value applications.

Cryo-Cell faces concentration risk because most of its business depends on continued demand for newborn cord blood and...

high

Competitive pressure in private cord blood banking

The company competes with roughly 25 other national private cord blood banks, which can pressure pricing and enrollment growth.

Scope
Core family banking revenue
Materiality
high
high

Regulatory changes for stem cell storage facilities

Management cites increased government regulation as a factor that could limit operations or raise compliance costs.

Scope
Processing, storage, and facility operations
Materiality
high
high

Cybersecurity and third-party hosting breaches

Stored healthcare and proprietary data could be exposed through external systems, creating legal, financial, and reputational damage.

Scope
Customer data and inventory systems
Materiality
high
medium

Strategic transaction or spinoff uncertainty

Management notes uncertainty around maximizing shareholder value through a strategic transaction or spinoff of Celle Corp.

Scope
Corporate structure and capital allocation
Materiality
medium
medium

NYSE American listing compliance

Failure to meet continued listing standards could lead to delisting and reduce liquidity and investor confidence.

Scope
Public market access
Materiality
medium
Revenue recognition on storage contracts
Affects deferred revenue, quarterly comparability, and reported growth rates
Allowance for doubtful accounts
Can change net revenue and operating profit
License and revenue-sharing agreements
Can affect reported revenue mix and margins
Stock-based compensation
Impacts SG&A and earnings quality

CRYO CELL INTERNATIONAL INC

CCEL · Services-Misc Health & Allied Services, NEC

Cryoport, Inc.

CYRX · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

IMMUCELL CORP /DE/

ICCC · In Vitro & In Vivo Diagnostic Substances

International Stem Cell CORP

ISCO · Pharmaceutical Preparations

Yubo International Biotech Ltd

YBGJ · Electromedical & Electrotherapeutic Apparatus

: 11/08/2026